Drug Profile
ADVM 053
Alternative Names: AAVrh10-C1EI; ADVM-053; ANN 002Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Weill Cornell Medical College
- Developer Adverum Biotechnologies
- Class Gene therapies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Complement C1 inhibitor protein expression stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hereditary angioedema
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Hereditary-angioedema in USA (IV)
- 01 Nov 2018 Adverum Biotechnologies decides not to submit IND for ADVM 053 for the treatment of Hereditary angioedema in the fourth quarter of 2018
- 27 Aug 2018 ADVM 053 receives Orphan Drug status for Hereditary angioedema in USA